Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PRKCI | P41743 | 3/20 | 0.47 |
| ▸ | METAP2 | P50579 | 2/20 | 0.47 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122734 | 0.92 | MEN1 (0.48) | MEN1NPC1KMT2APDE5AHIF1A | |
| SCHEMBL5123688 | 0.89 | METAP1 (0.61) | MEN1NPC1KMT2AHIF1ASMN1; SMN2 | |
| SCHEMBL5122140 | 0.89 | MEN1 (0.55) | MEN1NPC1KMT2APDE5AHIF1A | |
| SCHEMBL5113873 | 0.88 | SMN1; SMN2 (0.54) | MEN1NPC1KMT2APDE5ASMN1; SMN2 | |
| SCHEMBL5119994 | 0.87 | HIF1A (0.45) | MEN1NPC1KMT2APDE5AHIF1A | |
| SCHEMBL5130956 | 0.85 | POLB (0.48) | MEN1NPC1KMT2AHIF1AKDM4E | |
| SCHEMBL5127431 | 0.85 | PDE5A (0.47) | MEN1NPC1KMT2APDE5AHIF1A | |
| SCHEMBL23991504 | 0.84 | METAP2 (0.56) | MEN1NPC1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL5128968 | 0.83 | ALDH1A1 (0.44) | MEN1KMT2APDE5AHIF1ASMN1; SMN2 | |
| SCHEMBL5118041 | 0.83 | ALDH1A1 (0.48) | MEN1NPC1KMT2APDE5AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1685136-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005047292-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-6432950-B1 | ANTICANCER AGENTS; KILLING CANCER CELLS | CELL PATHWAYS | 2002-08-13 | — | — | US | disclosed |
| US-6133271-A | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives | CELL PATHWAYS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| US-6110920-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-08-29 | — | — | US | disclosed |
| EP-0920431-A1 | THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006722-A1 | THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045529-A1 | Use Of Thienopyrimidines | TIE1, DPYD, TK2 | MEN1 696/4885NPC1 4863/4885KMT2A 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.